Remdesivir plus Dexamethasone in COVID-19: A cohort study of severe patients requiring high flow oxygen therapy or non-invasive ventilation.

Gennaro De Pascale Salvatore Lucio CutuliSimone CarelliRikardo XhemalajTommaso RosàGiuseppe BelloJoel VargasMelania CesaranoLuca MontiniEloisa Sofia TanzarellaGabriele PintaudiMariangela Di MuroDomenico Luca GriecoMassimo Antonelli

Published in: PloS one (2022)

In COVID-19 critically ill patients receiving HFO or NIV, 28-day intubation rate was lower in patients who received Rem-Dexa and this finding corresponded to lower end-of-treatment clinical improvement. The individual contribution of either Remdesevir or Dexamethasone to the observed clinical effect should be further investigated.

Keyphrases

coronavirus disease
sars cov
end stage renal disease
low dose
ejection fraction
high dose
newly diagnosed
chronic kidney disease
peritoneal dialysis
cardiac arrest
prognostic factors
early onset
intensive care unit
bone marrow
respiratory syndrome coronavirus
combination therapy